Kura Oncology to Present First Ziftomenib-FLT3 Inhibitor Combination Trial Data at ASH 2026

PUBT · 21h ago
Kura Oncology to Present First Ziftomenib-FLT3 Inhibitor Combination Trial Data at ASH 2026
  • Kura Oncology and Kyowa Kirin will present initial ziftomenib-FLT3 inhibitor combination results at ASH Dec. 12-15, 2026, in New Orleans.
  • Trials evaluate ziftomenib with quizartinib in newly diagnosed AML or gilteritinib in relapsed or refractory disease, targeting NPM1/FLT3 co-mutated patients.
  • Longer-term frontline results with venetoclax and azacitidine support the ongoing Phase 3 KOMET-017 registrational trial; findings will be presented at the meeting.
  • An exploratory analysis indicates ziftomenib activity beyond NPM1-mutated and KMT2A-rearranged AML, supporting investigation in additional molecularly defined patient groups.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040902PRIMZONEFULLFEED9869882) on November 04, 2026, and is solely responsible for the information contained therein.